Home  »  Stocks to Invest   »  Jaguar Health Inc. (JAGX) stock gained during pre-...

Jaguar Health Inc. (JAGX) stock gained during pre-market trading. What should you know about it?

Jaguar Health Inc. (JAGX) stock surged by 5.88% at the last trading close while the JAGX stock price rises by 11.11% at the last check in the pre-market trading. Jaguar Health, Inc. is a commercial-stage pharmaceutical company focusing on developing new, plant-based, non-opioid, and sustainably derived prescription drugs for people and animals suffering from gastrointestinal discomfort, especially chronic, crippling diarrhea. Napo Pharmaceuticals, Inc., the fully owned subsidiary, is focused on creating and commercializing patented plant-based human gastrointestinal pharmaceuticals derived from plants safely obtained from rainforest areas.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored

What’s coming?

Jaguar Health sent a reminder today about the Innovators with Jane King interview with Lisa Conte, JAGX’s founder, president, and CEO, and Josh Mailman, the lead sponsor of the Dragon special purpose acquisition company (the “Dragon SPAC”), which will show during a webcast this Friday, April 23, 2021, to include a business analysis of Napo EU S.p.A. which is Jaguar’s wholly-owned subsidiary.

Recent Past Development

JAGX announced on April 15, 2021, that the at-the-market (“ATM”) financing program that Jaguar Health established with Ladenburg Thalmann & Co. on October 5, 2020, has been increased by $15.3 million for any future funding requirements. JAGX filed a registration statement and prospectus supplement on April 9, 2021, in accordance with its previously announced At “The Market Offering Agreement” with Ladenburg, as an agent, to increase the size of the at-the-market offering under which JAGX can offer and sell shares of Jaguar Health’s common stock from time to time via Ladenburg.

Lisa Conte, Jaguar’s president and CEO commented:

JAGX is ecstatic to have increased the ATM program’s potential. While Jaguar Health does not intend to issue any shares at this time, the upsized ATM system is intended to provide JAGX with future funding, if required, at the current market price at the time of sale, thus potentially priced at-the-market, or above-the-market, as defined by NASDAQ, based on timing.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts

385

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell

 

 

100% Free. Stop Anytime. No Spam